Oncolytics Q3: $2.4M Cash, Going-Concern Doubt, Nasdaq Bid-Price Notice
ONCY is trading near its 52-week low of $0.336 (10% above the low).
Summary
Oncolytics reported a $9.7M Q3 net loss with cash down to $2.4M, warned that current resources plus its ATM are not enough to fund twelve months of operations, and disclosed a Nasdaq minimum bid price deficiency with a January 15, 2027 deadline.
Key Events · Earnings and Guidance · ONCY
-
Going-Concern Warning Reiterated
With $2,430 thousand of cash at September 30, 2026, Oncolytics says existing resources plus capital available under its equity distribution arrangements are not sufficient to fund planned operations for at least twelve months.
-
Cash Burn Outpaces ATM Proceeds
Nine-month operating cash use was $22,346 thousand against $19,626 thousand of net ATM proceeds, cutting cash from $5,202 thousand at December 31, 2025 to $2,430 thousand.
-
ATM Pricing Deteriorates
Q3 ATM sales of 6,819,647 shares averaged $0.79; post-quarter sales of 3,633,301 shares through November 13, 2026 averaged $0.47 for $1,705 thousand gross and $1,654 thousand net.
-
Nasdaq Bid-Price Deficiency
A July 20, 2026 Nasdaq notice gives the company until January 15, 2027 to regain the $1.00 minimum bid; management may pursue a reverse stock split.
Analysis · ONCY · Life Sciences
Oncolytics closed September 30, 2026 with $2,430 thousand in cash and states plainly that existing resources, even combined with ATM capacity, will not fund planned operations for at least twelve months — a substantial-doubt going-concern warning. Over nine months the company burned $22,346 thousand in operating cash while raising $19,626 thousand net from ATM sales, meaning it is funding itself by selling stock into a falling price: post-quarter ATM sales averaged $0.47 per share versus $0.79 in Q3 and $0.86 for the nine months. Layered on top is the July 20, 2026 Nasdaq notice that the stock has traded below $1.00, with a compliance deadline of January 15, 2027 and a reverse split explicitly on the table. The clinical story (REO 033 Part B alignment with FDA, Fast Track in anal cancer) is intact, but the balance sheet now dictates the pace.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCY was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.2M. The 52-week trading range was $0.34 to $1.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.